Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma

Condition:   Angiosarcoma Interventions:   Drug: Paclitaxel;   Biological: mRNA plus Lysate-loaded Dendritic Cell Vaccine;   Drug: PEGYLATED-INTERFERON ALPHA-2A;   Drug: Filgrastim Sponsors:   M.D. Anderson Cancer Center;   Cancer Cures 4 Kids Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials